Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Dimebon - investigational treatment for Alzheimers and Huntington Disease
January 26, 2010
Dimebon for Alzheimer's and Huntington's Disease | medivation.com
Dimebon (latrepirdine) is a late-stage investigational clinical candidate for the treatment of Alzheimer’s and Huntington diseases. It is being developed by a partnership between Medivation and Pfizer. Although a weak cholinesterase inhibitor, the MOA is thought to be through the preservation of mitochondrial function.
-
UCB's Vimpat (lacosamide) receives FDA approval
November 3, 2008
UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
FDA has approved lacosamide for add-on therapy of partial onset seizures. It will be marketed by UCB under the brand name Vimpat.
-
Artificial Cervical Disc Looks Promising
January 25, 2008
Artificial Disc Versus Fusion: A Prospective, Randomized Study With 2-Year Follow-up on 99 Patients | www.medscape.com
Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.
-
Lacosamide Should Solidify UCB as CNS Drug Leader
November 30, 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures | www.reuters.com
UCB has filed new drug application for regulatory approval for lacosamide through FDA and European Medicines Agency. Primary indication would be the treatment of partial onset seizures (epilepsy)
-
Hydrocodone -- The Return of Hill Billy Heroin?
August 22, 2007
Painkiller Widely Abused in South | www.washingtonpost.com
The article describes the increase in hydrocodone abuse, especially in the Southern and Rural US.
-
Medical Tourism -- Bargain or Boondoggle?
August 21, 2007
American's Gamble for Bargain Surgery Abroad | www.medpagetoday.com
The article describes several examples of medical tourism with different motivations and risks involved.
-
Novel Experimental Approach to Gliomas
August 17, 2007
Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab | www.pipelinereview.com
The articel discusses Oncoscience AG, the european partner of YM BioSciences experimenal treatment for gliomas. It is based on a monoclonal antibody to EGFR and is being tested in combination with other treatments including radiation.
-
New Myasthenia Treatment Makes Sense
August 16, 2007
New Treatment Boosts Muscle Function In Myasthenia Gravis | www.medicalnewstoday.com
The article reports on an open label study recently published in Neurology. Apparently a new treatment (oral EN101 antisense) appears to be effective at improving muscle strength and reducing fatigue in people with MG.
-
New MS treatments to be based on genetic breakthrough?
August 13, 2007
Genetic breakthrough offers MS sufferers hope of new treatment | www.timesonline.co.uk
Two genes have been linked to an increased risk for the development of MS. Several researchers speculate on the ipact this may have on future treatments.
-
Branded drugs have value in epilepsy, but future is unclear
July 30, 2007
Industry Fights Switch to Generics for Epilepsy | online.wsj.com
The epilepsy foundation and major drug manufacturers have teamed up to protect reimbursments for branded anti-epilepsy drugs.
-
Branded drugs have value in epilepsy, but future is unclear
July 30, 2007
Industry Fights Switch to Generics for Epilepsy | online.wsj.com
The epilepsy foundation and major drug manufacturers have teamed up to protect reimbursments for branded anti-epilepsy drugs.
-
Device attacks ischemic stroke without mercy
July 23, 2007
Multi MERCI(R) Trial Demonstrates Better Outcomes For Patients Suffering Ischemic Stroke | www.medicalnewstoday.com
The article reports on the results of recent research showing the effectiveness of the Merci(R) Retrieval System. This pivotal study has contributed to the device receiving FDA approval
-
May 23, 2007
New Test May Allow For Rapid Detection Of Salmonella In Meat | www.medicalnewstoday.com
PCR analysis of meat for Salmonella was compared to traditional culture methods The PCR technique showed a relatively high sensitivity and specificity for the organism much more rapidly
-
Lamotrigine superior for partial epilepsy?
April 3, 2007
Research Finds Newer Drug for Partial Epilepsy Is Superior But Old Tops New For Generalised Seizures | www.medicalnewstoday.com
The article reports on a British study suggesting that lamotrigine and valproic acid are respectively the best first line drugs for partial and generalized onset epilepsy.
-
Avicena begins NIH funded phase III trial of PD-02
April 3, 2007
Avicena Announces Patient Enrollment in National Institutes Of Health (NIH) Phase III Parkinson's Disease Trial | www.medicalnewstoday.com
PD-02 is an ultra-pure form of creatine which may slow the progress of Parkinson’s Disease. A federal government sponsored phase III clinical trial has just begun to evaluate its efficacy.
-
April 3, 2007
Suffering boomers want to fill Vioxx void | www.contracostatimes.com
The article states that Cox-2 inhibitors may be making a comeback to treat arthritis pain
-
Duloxetine (Cymbalta) gets new FDA approval
April 3, 2007
FDA Approves Duloxetine for Anxiety | journals.elsevierhealth.com
Duloxetine has received FDA approval for the treatment of generalized anxiety disorder, based on the results of three studies of more than 800 subjects.
-
Anterior plating has higher fusion rate for single-disc-level procedures
April 3, 2007
Study Compares Benefits Of Surgical Treatments For Degenerative Spinal Disease - Higher Success Rates Shown In Procedures Using Plate System | www.medicalnewstoday.com
This article reports on a meta-analysis comparing different surgical procedures for cervical fusion. Approaches with anterior plating provided the highest rates of fusion.
-
New device looks promising for improving motor function after stroke
April 3, 2007
MIT Brace Aids Stroke Recovery - Worn On The Arm, NeuroRobotic Device Is Lightweight, Portable | www.medicalnewstoday.com
A new robotic brace developed by MIT researchers allows patients to have improved limb use by facilitating joint movement.
-
April 2, 2007
Vaccines: What Does Cervical Cancer Have To Do With Chickenpox? | blogs.wsj.com
The article discusses current problems with the apparent short life of the chicken pox vaccine and mandatory vaccinations.
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.